Les médicaments GLP-1 imitent une hormone intestinale qui coupe l'appétit, et ils font davantage pour le poids et la santé métabolique que tout médicament avant eux. Les fondamentaux font toujours le travail de fond : aliments bruts, activité régulière, sommeil et suffisamment de protéines. Dans de grands essais randomisés, le sémaglutide a produit environ 15 % de perte de poids et le tirzépatide environ un cinquième. Tous deux ont abaissé la glycémie à long terme d'environ deux points de pourcentage dans le diabète de type 2.
Le sémaglutide a aussi réduit d'environ un cinquième les événements cardiovasculaires majeurs chez des personnes en surpoids atteintes de maladie cardiaque et sans diabète. Ils comportent des compromis : effets digestifs fréquents au début, une part de muscle perdue en même temps que la graisse, et un poids qui revient lorsque le médicament est arrêté. Ce sont des médicaments sur ordonnance, et savoir si l'un d'eux convient est une décision prise avec un prescripteur.
Findings & Outcomes
What It Is
GLP-1 medicines are engineered copies of a gut hormone the body releases after eating, one that curbs appetite. The best known is semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight, acts on two gut-hormone receptors at once. Most are given as a weekly injection, and an oral form exists. They began as diabetes treatments and turned out to produce weight loss and heart protection well beyond earlier diabetes drugs.
These drugs act on the biology of appetite. Hunger and fullness are controlled by hormones. In many people these hold body weight around a higher set point, making weight hard to lose and easy to regain. Much of that pressure is manufactured. Ultra-processed foods engineered around fat, sugar, and salt supply more than half of the calories in the average American adult's diet. That food environment is a driver of the weight these drugs treat. The GLP-1 drugs act on the appetite system directly. That is why they produce weight loss diet and exercise alone rarely reach.
What It Does
The largest and most certain effect is weight. In large randomized trials semaglutide takes off about 15% of body weight, tirzepatide closer to a fifth, more than any drug before them. In type 2 diabetes they also lower long-term blood sugar (HbA1c) by around two percentage points.
Over years, in people with diabetes or established heart disease, these drugs prevent major cardiovascular events, slow kidney disease, and lower the chance of dying from any cause. Semaglutide cut major cardiovascular events by about a fifth in people who were overweight and had heart disease but no diabetes. It was the first GLP-1 drug shown to do so without diabetes in the picture.
At the approved weekly dose, semaglutide now improves both the inflammation and the early scarring of metabolic (MASH) liver disease. Trials are extending into obstructive sleep apnea and other conditions.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Weight And Fat Loss
Semaglutide took off about 15% of body weight in obesity
People with obesity lost about 15% of their body weight over roughly sixteen months on weekly semaglutide, compared with about 2% on a dummy injection, and most lost at least 5%.
STEP 1 was a 68-week randomized, double-blind trial in 1,961 adults with a BMI of 30 or more (or 27 with a weight-related condition) and no diabetes, both arms receiving lifestyle counseling. Mean change in body weight was -14.9% with semaglutide 2.4 mg weekly versus -2.4% with placebo, a treatment difference of 12.4 percentage points. 86.4% of the semaglutide group lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Weight fell steadily over the titration period and then plateaued.
The study · 1
Wilding et al., once-weekly semaglutide in adults with overweight or obesity (STEP 1) · N Engl J Med 2021;384:989-1002
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Tirzepatide took off up to 20.9% of body weight at its top dose
On the highest dose of tirzepatide, people with obesity lost about a fifth of their body weight over eighteen months, more than the roughly 15% seen with semaglutide.
SURMOUNT-1 was a 72-week randomized, double-blind trial in 2,539 adults with obesity (or overweight with a complication) and no diabetes. Mean weight change was -15.0%, -19.5% and -20.9% at tirzepatide 5, 10 and 15 mg weekly versus -3.1% on placebo. Tirzepatide is a dual agonist acting on both the GLP-1 and the GIP receptor, and 57% of those on the 15 mg dose (50% at 10 mg) lost at least a fifth of their body weight.
The study · 1
Jastreboff et al., tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) · N Engl J Med 2022;387:205-216
Environ les deux tiers du poids perdu sont repris dans l'année suivant l'arrêt
Après l'arrêt du sémaglutide, les personnes ont repris environ les deux tiers du poids qu'elles avaient perdu en un an, et leur tension artérielle et leur glycémie sont revenues progressivement vers leurs valeurs de départ.
Cette extension a suivi 327 participants de STEP 1 pendant un an après l'arrêt du sémaglutide et de l'intervention sur le mode de vie à la semaine 68. Les participants ont repris environ les deux tiers (11.6 points de pourcentage sur les 17.3 % perdus) de leur perte de poids antérieure à la semaine 120, et les améliorations cardiométaboliques, notamment la pression artérielle et l'hémoglobine glyquée, sont également revenues vers les valeurs initiales. Ce schéma reflète le fait que le médicament n'agit que pendant son utilisation et ne réinitialise pas le point d'équilibre du corps.
Comme l'effet dépend du maintien du traitement, il faut planifier dès le départ pour le long terme, y compris le coût et les habitudes qui soutiennent le résultat.
The study · 1
Wilding et al., weight regain and cardiometabolic effects after withdrawal of semaglutide, the STEP 1 trial extension · Diabetes Obes Metab 2022;24:1553-1564
Blood Sugar
Both drugs cut HbA1c about 2 percentage points in type 2 diabetes
In type 2 diabetes, both drugs lowered long-term blood sugar (HbA1c) by around two percentage points, a large drop, with tirzepatide slightly ahead of semaglutide.
SURPASS-2 was a 40-week open-label randomized trial in 1,879 adults with type 2 diabetes inadequately controlled on metformin (mean baseline HbA1c 8.28%). HbA1c fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5, 10 and 15 mg and by 1.86 on semaglutide 1 mg. Tirzepatide was non-inferior and superior to semaglutide at all three doses, and produced greater weight loss as well.
The study · 1
Frias et al., tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) · N Engl J Med 2021;385:503-515
Heart And Vascular
Semaglutide cut major cardiovascular events 20% in obesity without diabetes
In people who were overweight and already had heart disease but not diabetes, semaglutide lowered the rate of heart attacks, strokes and cardiovascular deaths by about a fifth over three years.
SELECT was a randomized, double-blind trial in 17,604 adults aged 45 or over who were overweight or obese and had established cardiovascular disease but not diabetes. Over a mean follow-up of 39.8 months, the primary composite endpoint occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo (HR 0.80, 95% CI 0.72 to 0.90). This was the first trial to show a GLP-1 drug prevents cardiovascular events in people without diabetes, and the benefit appeared partly separable from the weight lost.
The study · 1
Lincoff et al., semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT) · N Engl J Med 2023;389:2221-2232
Semaglutide cut major cardiovascular events 26% in high-risk type 2 diabetes
In people with type 2 diabetes at high heart risk, semaglutide lowered heart attacks, strokes and cardiovascular deaths by about a quarter over two years.
SUSTAIN-6 was a 104-week randomized, double-blind pre-approval cardiovascular safety trial in 3,297 adults with type 2 diabetes at high cardiovascular risk. The primary composite occurred in 6.6% on semaglutide versus 8.9% on placebo (HR 0.74, 95% CI 0.58 to 0.95), driven mainly by a reduction in nonfatal stroke and nonfatal heart attack, not cardiovascular death.
The study · 1
Marso et al., semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) · N Engl J Med 2016;375:1834-1844
Longevity And Mortality
Les médicaments GLP-1 ont réduit la mortalité toutes causes confondues de 12 % dans le diabète de type 2
En regroupant les grands essais sur les événements cardiaques chez les diabétiques, ces médicaments ont réduit le risque de décès toutes causes confondues d'environ 12 %, et ont aussi diminué les événements cardiaques et rénaux.
Cette revue systématique et méta-analyse a regroupé 8 essais randomisés sur les événements cardiovasculaires portant sur des agonistes des récepteurs du GLP-1 chez 60,080 adultes atteints de diabète de type 2. La mortalité toutes causes confondues a été réduite de 12 % (HR 0.88, IC à 95 % 0.82 à 0.94), le critère composite d'événements cardiovasculaires indésirables majeurs à trois points de 14 % (HR 0.86), et un critère composite rénal de 21 % (HR 0.79). Les effets étaient globalement cohérents entre les différents médicaments de la classe.
The study · 1
Sattar et al., cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in type 2 diabetes, systematic review and meta-analysis · Lancet Diabetes Endocrinol 2021;9:653-662
Digestion
Les nausées ont atteint environ 44 % au début, et environ 7 % ont arrêté le médicament
Les nausées sont l'effet secondaire le plus fréquent, touchant près de la moitié des personnes au début, ainsi que la diarrhée, les vomissements et la constipation. Elles sont généralement légères à modérées et s'atténuent à mesure que l'organisme s'adapte, bien que certaines personnes arrêtent le traitement à cause d'elles.
Dans l'essai STEP 1 sur l'obésité (1,961 adultes, 68 semaines), les troubles gastro-intestinaux étaient les événements indésirables les plus fréquents avec le sémaglutide 2.4 mg : nausées chez environ 44 % versus 18 % sous placebo, avec diarrhée, vomissements et constipation également augmentés. La plupart des événements étaient transitoires et légers à modérés, concentrés pendant la période d'augmentation progressive de la dose. L'arrêt pour événements indésirables était d'environ 7 % sous sémaglutide contre 3 % sous placebo, principalement en raison de symptômes gastro-intestinaux.
Augmenter la dose lentement, prendre des repas plus petits et arrêter de manger dès la satiété réduisent les symptômes ; des symptômes sévères ou persistants sont une raison de demander au prescripteur de ralentir le rythme ou de faire une pause.
The study · 1
Wilding et al., once-weekly semaglutide in adults with overweight or obesity (STEP 1), adverse events · N Engl J Med 2021;384:989-1002
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Le sémaglutide 2.4 mg a amélioré la fibrose hépatique chez 36.8 % versus 22.4 % et a résolu la stéatohépatite chez 62.9 % versus 34.3 %
Chez les personnes atteintes de la forme inflammatoire de la stéatose hépatique avec cicatrisation précoce, le sémaglutide à la dose hebdomadaire approuvée de 2.4 mg a résolu l'inflammation chez environ 63 % versus 34 % sous placebo et a amélioré la cicatrisation chez 36.8 % versus 22.4 %. Un essai antérieur à une dose quotidienne plus faible avait résolu l'inflammation mais n'avait pas modifié la cicatrisation.
L'essai de phase 3 ESSENCE a randomisé 1,197 adultes atteints de stéatohépatite associée à un dysfonctionnement métabolique (MASH) confirmée par biopsie et de fibrose hépatique de stade F2 ou F3, selon un ratio de 2:1, pour recevoir soit le sémaglutide hebdomadaire à 2.4 mg, soit un placebo. Lors de l'analyse intermédiaire prévue à la semaine 72 chez les 800 premiers patients, une réduction de la fibrose hépatique sans aggravation de la stéatohépatite est survenue chez 36.8 % sous sémaglutide versus 22.4 % sous placebo, et une résolution de la stéatohépatite sans aggravation de la fibrose chez 62.9 % versus 34.3 %, les deux P < 0.001 ; 32.7 % ont atteint les deux objectifs. Un essai de phase 2 antérieur de 72 semaines chez 320 adultes, utilisant une dose quotidienne plus faible de 0.4 mg, avait résolu la stéatohépatite chez 59 % versus 17 %, mais n'avait pas significativement amélioré le stade de fibrose.
À la dose hebdomadaire approuvée, le sémaglutide améliore désormais à la fois l'inflammation et la cicatrisation précoce de la MASH, ce qui explique que le bénéfice hépatique soit l'une des raisons pour lesquelles il peut être envisagé lorsque la MASH survient avec obésité ou diabète de type 2, sous la conduite d'un spécialiste. La question de savoir s'il prévient la cirrhose et ses complications est encore en cours d'évaluation.
The studies · 2
Semaglutide in MASH with fibrosis, ESSENCE, NEJM 2025 · N Engl J Med 2025
Newsome et al., a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis · N Engl J Med 2021;384:1113-1124
Kidney Disease
Le sémaglutide a réduit de 24 % les événements rénaux majeurs dans la maladie rénale diabétique
Chez les personnes atteintes de diabète de type 2 et d'une maladie rénale déjà présente, le sémaglutide a réduit d'environ un quart le risque d'insuffisance rénale et de déclin rénal majeur.
FLOW était un essai randomisé en double aveugle portant sur 3,533 adultes atteints de diabète de type 2 et de maladie rénale chronique. Le critère composite principal d'événements rénaux majeurs (survenue d'une insuffisance rénale, baisse soutenue du DFGe d'au moins 50 %, ou décès d'origine rénale ou cardiovasculaire) a été réduit de 24 % avec le sémaglutide (HR 0.76, IC à 95 % 0.66 à 0.88). L'essai a été arrêté précocement pour efficacité, et le sémaglutide a également réduit les événements cardiovasculaires et la mortalité toutes causes confondues.
The study · 1
Perkovic et al., effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW) · N Engl J Med 2024;391:109-121
Muscle And Strength
Environ un quart du poids perdu est du muscle, pas de la graisse
Environ un quart du poids perdu avec ces médicaments est constitué de muscle et d'autres tissus maigres, et non de graisse, comme pour une perte de poids obtenue par d'autres moyens. Le corps n'est pas devenu proportionnellement moins musclé, la préoccupation porte donc sur la masse musculaire totale perdue, ce qui compte davantage avec l'âge.
Cette méta-analyse a regroupé 22 essais randomisés (2,258 participants) avec mesure de la composition corporelle. Les agonistes des récepteurs du GLP-1 ont réduit le poids corporel total d'environ 7.8 lb (3.55 kg), la masse maigre représentant environ 25 % de la perte. La masse maigre relative, exprimée en pourcentage de variation par rapport à la valeur initiale, n'a pas été affectée, indiquant que le corps n'est pas devenu proportionnellement moins musclé. Le liraglutide a été le seul agent à réduire le poids sans diminuer significativement la masse maigre, tandis que le sémaglutide et le tirzépatide étaient les plus efficaces pour la perte de graisse et parmi les moins efficaces pour préserver la masse maigre.
Un apport suffisant en protéines et un entraînement de résistance régulier sont les leviers ayant démontré protéger le muscle pendant la perte de poids, c'est pourquoi ils doivent accompagner le médicament, et non le suivre, en particulier pour les personnes âgées.
The study · 1
Effect of GLP-1 receptor agonists and co-agonists on body composition, network meta-analysis · Metabolism 2025
How It Works
These drugs work on three linked systems at once. In the brain, they act on appetite centers to reduce hunger and the urge to eat between meals. In the stomach, they slow how fast a meal empties, so fullness comes sooner and lasts longer and the rise in blood sugar after eating is gentler. In the pancreas, they raise insulin release only when blood sugar is high. That is why, used alone, they rarely push it too low. For the metabolic system underneath all of this, see insulin and glucose handling.
Anatomy of the Practice
1The gut hormone they copy
The gut releases GLP-1 after eating, then breaks it down within minutes. These drugs copy that hormone in a form that resists breakdown, so a single weekly injection keeps the signal going for days. Because they are proteins, they break down if swallowed, so most are injected. The dose is raised in steps over several weeks to let the gut adjust.
2The two-receptor drugs
Tirzepatide adds a second target, the GIP receptor, alongside GLP-1. GIP, another gut hormone, helps drive insulin release and fat storage. Acting on both receptors appears to produce more weight loss than GLP-1 alone. That is the leading explanation for tirzepatide's larger effect.
3Why appetite falls
In trials that measured energy use, the weight loss comes almost entirely from eating less, with little change in how many calories the body burns. Slower stomach emptying means food stays longer and fullness comes sooner. Brain signaling lowers hunger and the urge to eat between meals. Less food goes in, and the body draws on its own fat stores.
The Trade-offs and What Is Not Yet Known
Gut side effects are the most common cost of these drugs. Raising the dose slowly is the main lever that keeps them manageable, though a minority stop the drug because of them.
Some of the loss is lean muscle, and older adults start with less to spare, so how much you lose matters more with age. Enough protein and regular resistance training are the two levers shown to protect it: see protein and muscle and resistance training.
The effect lasts only while the drug is taken. The weight and the metabolic gains return when the drug stops, so these are treatment for an ongoing condition, planned over years.
Some things are not settled. The longest trials run about three to four years, so the open questions are all about the long run:
- Decade-scale safety is not yet established.
- Most of the weight and heart evidence comes from people who were obese or already at high cardiovascular risk, so the benefit in lower-risk, general use is less certain.
Using Them Well
Starting a GLP-1 drug is a decision to make with a prescriber. What to bring to that conversation, and how to get the most from the treatment if it fits:
Whole food, steady activity, sleep, and enough protein are the foundation of weight and metabolic health. The drug builds on these habits, and they stay whether or not you go on the medicine. Keep them from the start.
Whether one fits depends on your weight, your blood sugar, your heart and kidney health, and your other conditions and medicines. A clinician sets the starting dose, raises it in steps, and monitors how you respond.
Raising the dose slowly is what keeps gut symptoms manageable. Eating smaller meals, slowing down, and stopping when full tend to help. If symptoms are severe or lasting, the prescriber can slow the pace or pause the increase.
Think from the outset about the plan over years, and the eating and training habits that support the result whether or not you stay on the drug.
Go Deeper
- Type 2 diabetes: where these drugs change long-term outcomes, next to the lifestyle levers that matter most in early disease.
- Weight and metabolic health: the whole picture of fat loss, where these drugs sit after the basics of training, protein and whole food.
- Peptides: the wider peptide market, where the GLP-1 drugs are the approved, trial-tested end.
- Protein and muscle: the daily protein target that preserves lean mass while you lose fat.
- Resistance training: the minimum effective dose of resistance work, and why it holds muscle during weight loss.
The Chinese Medicine View
These are modern drugs, isolated and engineered in the last few decades, so there is no classical Chinese entry for any of them. No historical text assigns a channel, a temperature or a flavor to a GLP-1 medicine, and no traditional formula contains one.
These drugs act on functions Chinese medicine has always reasoned about. The Spleen, in this framework, governs the transformation and transport of food into usable substance. The Spleen and Stomach are the two organs it reads as the seat of appetite, fullness and digestion. When that function is weak, the tradition describes food and fluid failing to move and transform, gathering instead as Dampness and Phlegm. Those patterns are often laid over the modern picture of carrying excess weight with a sluggish metabolism. A drug that slows the stomach, reduces appetite and shifts how the body handles food is, in a loose sense, acting on those same functions.
The tradition would also draw a distinction. The drug reduces appetite. It does not, in this framework, strengthen the Spleen function itself. Chinese medicine reads three signs (persistent poor appetite, early fullness and fatigue after eating) as a depleted Spleen. In this framework those signs are a depletion to correct. So the drug addresses the symptom, appetite, while the tradition's own aim, a Spleen that transforms food well on its own, is left untouched. That gap is one reading of why the effect fades once the drug is stopped.
Cautions For These Medications
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Les médicaments GLP-1 ont augmenté d'environ un tiers les maladies de la vésicule biliaire et des voies biliaires
Cette revue systématique et méta-analyse a regroupé 76 essais randomisés (103,371 patients, âge moyen 57.8 ans, 40.5 % de femmes). La randomisation à un agoniste des récepteurs GLP-1 a été associée à un risque 37 % plus élevé de maladie de la vésicule biliaire ou des voies biliaires (RR 1.37, IC à 95 % 1.23 à 1.52), y compris cholélithiase (RR 1.27) et cholécystite (RR 1.36). Le risque était plus élevé à doses plus élevées (RR 1.56) et avec un traitement plus long, et était le plus important dans les essais sur la perte de poids (RR 2.29) par rapport aux essais sur le diabète (RR 1.27), ce qui concorde avec le fait que la perte de poids rapide fait partie du mécanisme. Les essais ont rapporté des risques relatifs sans chiffre absolu précis.He et al., association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases, systematic review and meta-analysis of randomized clinical trials
These are prescription medicines, and the starting decision sits with a clinician
Whether one fits, at what dose, and how fast to raise it depends on your full picture: blood sugar, heart and kidney health, other conditions and other medicines. Start, change, or stop one only with your prescriber. Compounded or gray-market versions sold outside a pharmacy carry no check on what is actually in the vial, and dosing errors with them have sent people to the hospital.
Not in pregnancy or when trying to conceive
These drugs are not recommended in pregnancy, and guidance is to stop them well before a planned pregnancy because they clear slowly. Anyone who could become pregnant should discuss contraception and timing with a prescriber. Because early appetite suppression can reduce how well the pill is absorbed, a backup method is often advised. Rapid weight loss around conception is itself a reason for medical guidance.
Gallbladder, biliary and pancreas
Across randomized trials these drugs raise the risk of gallbladder and biliary disease by about a third. The risk is higher at larger doses and in weight-loss use, partly a consequence of rapid weight loss itself. Pancreatitis has been reported as well. Severe, persistent abdominal pain, especially with vomiting, is a reason to seek care promptly; do not wait it out.
A thyroid contraindication for some families
In rodent studies these drugs caused thyroid C-cell tumors. It has not been shown in people. Still, the drugs are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, or the genetic syndrome MEN 2. Raise that history before starting.
Severe or lasting gut symptoms
Nausea, vomiting, diarrhea and constipation are the usual side effects and are most common in the first weeks and while the dose climbs. For most people they are mild to moderate and ease with time and a slower increase. If they are severe or lead to dehydration, the prescriber should adjust the plan.
Tell your team before surgery or an endoscopy
Because these drugs slow how fast the stomach empties, food can remain longer than expected. That raises the risk of breathing stomach contents into the lungs under sedation or general anesthesia. Anesthesiology guidance now asks that your prescriber and procedure team know you take one. They can then hold a dose or take extra precautions before surgery or an endoscopy. Do not stop on your own, but do make sure they know.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
How much weight do people lose on GLP-1 medicines?
Averaged across the big trials, adults with obesity lost about 15% of body weight over 16 months on weekly semaglutide, against about 2% on a dummy injection. Tirzepatide's highest dose reached about a fifth. These are averages; individual results vary widely, and the loss builds gradually as the dose climbs. Those figures come from people without diabetes, in type 2 diabetes the weight loss tends to run somewhat smaller.
Do these drugs help the heart, or only weight?
They do more than trim weight. The cardiovascular benefit (fewer heart attacks, strokes, and cardiovascular deaths over roughly three years) is larger than weight loss alone would predict. That points to effects on blood vessels and inflammation beyond the pounds lost. In type 2 diabetes, semaglutide lowered cardiovascular events as well. That combination of weight, blood-sugar, and heart benefit is why these drugs are used for more than weight loss.
What happens if I stop taking one?
In the extension of the semaglutide weight trial, people regained about two-thirds of what they had lost within a year of stopping.
Blood pressure and blood-sugar markers drifted back toward where they started. Building steady eating and training habits alongside the drug holds on to more of the result if the drug is ever stopped.
Will I lose muscle on a GLP-1 medicine?
Some. When the body loses a large amount of weight, part of it is muscle. Pooled trial data put that share at about a quarter of the total, similar to weight loss by any means. Lean mass fell in step with total weight, the share of the body that is muscle stayed about the same.
Are GLP-1 medicines a cure for type 2 diabetes?
They treat type 2 diabetes powerfully without curing it. Blood sugar falls sharply on both drugs, but it tends to rise again if the drug stops. Early type 2 diabetes can sometimes reach remission through weight loss itself. These drugs drive that weight loss but do not, on their own, make the remission permanent. They work best inside care that also uses the lifestyle levers on the type 2 diabetes page.
They are expensive. Are compounded or online versions the same thing?
Not reliably. Brand-name GLP-1 drugs are costly, and coverage varies widely. That gap has driven a large market in compounded and online versions. Those are not held to the same manufacturing checks, so what is in them is not guaranteed. If cost is the barrier, a prescriber can walk through approved brands like Wegovy or Zepbound and any access programs.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 13 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.